-transparent.png){kind=logo}
The emergence of multidrug resistance(MDR) is a major problem in cancer chemotherapy. Many compounds are developed to reverse MDR, and some of them are under clinical trials. Among them, MS-209, a novel quinoline derivative, is one of the most potent MDR reversing agents. MS-209 at 3 microM effectively reverses MDR in various cell lines in vitro. MS-209 directly interacts with P-glycoprotein and inhibits the P-glycoprotein-mediated drug transport. Oral administration of MS-209 combined with anticancer drugs markedly increases the life span of mice bearing MDR tumor cells without causing serious side effects. Thus, MS-209 is an orally active and potent MDR reversing drug without serious side effects.
M Naito, and
O Nakanishi, and
T Tsuruo
May 1991,
Cancer research,
M Naito, and
O Nakanishi, and
T Tsuruo
October 2005,
Biopharmaceutics & drug disposition,
M Naito, and
O Nakanishi, and
T Tsuruo
February 1999,
Biochemical and biophysical research communications,
M Naito, and
O Nakanishi, and
T Tsuruo
June 1997,
Journal of medicinal chemistry,
M Naito, and
O Nakanishi, and
T Tsuruo
January 1997,
Cancer chemotherapy and pharmacology,
M Naito, and
O Nakanishi, and
T Tsuruo
March 1999,
Bioorganic & medicinal chemistry letters,
M Naito, and
O Nakanishi, and
T Tsuruo
January 1998,
Cancer chemotherapy and pharmacology,
M Naito, and
O Nakanishi, and
T Tsuruo
July 2001,
Japanese journal of cancer research : Gann,
M Naito, and
O Nakanishi, and
T Tsuruo
January 1998,
Anticancer research,
M Naito, and
O Nakanishi, and
T Tsuruo
February 2020,
Journal of helminthology,
